AOD-9604 is a modified peptide fragment of human growth hormone (HGH) that has been specifically engineered to target fat metabolism — without the unwanted hormonal effects that accompany full HGH administration. For those looking for a targeted fat loss peptide that works at the metabolic level, AOD-9604 represents one of the most elegant and precise tools in the peptide science toolkit.
What Is AOD-9604?
AOD-9604 — short for Anti-Obesity Drug 9604 — is a synthetic peptide fragment corresponding to amino acids 177 through 191 of the human growth hormone molecule, with a tyrosine residue added at the N-terminus for stability. It was developed by researchers at Monash University in Australia and investigated by Metabolic Pharmaceuticals Ltd. as a potential treatment for obesity, reaching Phase 3 clinical trials.
What makes AOD-9604 uniquely valuable is that it replicates the fat-burning activity of growth hormone without stimulating IGF-1 production or the insulin resistance, water retention, or growth-promoting effects associated with full-length HGH. In essence, it captures the lipolytic (fat-burning) action of GH while leaving its anabolic (growth-promoting) action behind.
How Does AOD-9604 Work?
Human growth hormone exerts its effects on fat metabolism through a specific region of the GH molecule. AOD-9604 isolates and replicates this region, allowing it to stimulate lipolysis by activating beta-3 adrenergic receptors and triggering the breakdown of stored fat — particularly in adipose tissue. It also actively suppresses the formation of new fat cells (lipogenesis). Because AOD-9604 does not bind to the GH receptor in the same way as full HGH, it does not stimulate IGF-1 or promote cell proliferation — avoiding the side effects associated with HGH therapy.
Research also suggests that AOD-9604 may have cartilage-protective and regenerative properties, potentially making it useful for joint support beyond its fat loss applications.
Benefits of AOD-9604
- Targeted fat loss: AOD-9604 specifically promotes the breakdown of stored fat, particularly stubborn adipose deposits.
- No blood sugar impact: Unlike HGH, AOD-9604 does not affect blood glucose or insulin sensitivity — making it significantly safer for metabolic health.
- No IGF-1 stimulation: The peptide does not raise IGF-1 levels, eliminating concerns about cell proliferation or growth-promoting effects.
- Potential cartilage support: Emerging data suggests AOD-9604 may support cartilage repair, which could benefit individuals with joint concerns alongside fat loss goals.
- Excellent safety profile: Phase 3 trials demonstrated AOD-9604 was well-tolerated across a large patient population with no serious adverse events attributable to the drug.
Research Summary
AOD-9604 underwent extensive clinical investigation by Metabolic Pharmaceuticals, reaching Phase 3 trials before development was halted due to insufficient efficacy for FDA approval as a standalone obesity treatment at the doses studied. However, the safety data collected across thousands of patients is highly reassuring.
Preclinical studies in animal models consistently demonstrate significant reductions in body fat in obese rodents treated with AOD-9604, with preferential loss of adipose tissue over lean mass. The compound received GRAS (Generally Recognized As Safe) status from the FDA in 2014 — a designation reflecting an excellent safety track record.
AOD-9604 is frequently combined with other peptides like CJC-1295, Ipamorelin, or BPC-157 in clinical protocols targeting body composition, recovery, and metabolic health.
Who Is AOD-9604 For?
AOD-9604 is best suited for:
- Individuals with stubborn fat deposits that are resistant to diet and exercise alone
- Those who want the fat-burning effects of growth hormone without the risks of full HGH therapy
- Metabolically cautious patients — particularly those with insulin resistance, pre-diabetes, or concern about IGF-1 elevation
- Athletes and active individuals looking to improve body composition while maintaining or building lean muscle mass
- Anyone seeking to stack a targeted fat loss peptide with a broader peptide protocol for comprehensive body recomposition
Administration and Protocols
AOD-9604 is typically administered via subcutaneous injection, usually in the morning in a fasted state to maximize its lipolytic effect. Standard doses in clinical and research settings have ranged from 250 to 500 mcg per day. Some protocols cycle the peptide on a 5 days on, 2 days off schedule to maintain receptor sensitivity.
At BioSim Peptides, we see AOD-9604 as a precision tool — one that delivers a targeted metabolic effect without the systemic risks of growth hormone. When paired with a disciplined nutrition protocol and consistent training, it can make a meaningful difference in body composition outcomes, particularly for those who have plateaued on conventional approaches.
